Feeds

Final drug trial victim out of the woods

As placebo man balks at follow-ups

Protecting against web application threats using SSL

All of the volunteers given an experimental immune drug in a London trial have now made it off the critical list at Northwick Park hospital.

The last of six men given biotech firm TeGenero's TGN1412 compound is now fully conscious and looks set to make a full recovery.

Intensive care clinical director Dr Ganesh Suntharalingam said: "We are delighted that the six patients have come through safely from the most critical stage of their condition."

He praised intensive care staff for how they dealt with the victims' very serious condition when they were transferred there from a private testing unit more than three weeks ago.

TeGenero said today its preliminary investigations showed it had followed all correct procedures in the animal testing phase of the drug. It also says the problem was unforseeable based on preclinical results (see here for why many think the problems might have been foreseeable though).

Watchdog the Medicines and Healthcare products Regulatory Agency (MHRA) agreed, saying it hasn't been able find a problem with how the trial was carried out.

It also couldn't find evidence of contamination of the drug. Some had speculated bacterial toxins might be responsible for the multiple organ failure.

MRHA added that its findings are not yet conclusive, but that the suspected flaws in the action of the drug itself were the most likely cause. The Secretary of State for Health is assembling a panel of experts to investigate why the animal trials didn't pick up the near-deadly complications.

Meanwhile, Raste Khan, 23, one of the men given a harmless placebo, appeared in The Sun today, saying he was still traumatised by what he saw during the trials. "I still feel haunted by it and I know my family have been extremely upset. I am too frightened even to get sleeping pills from the doctor."

He claims test contractor Parexel is demanding he honour the terms of his contract by attending follow-ups in order to pocket his £2,000 volunteer fee.

Testing contractor Parexel was unavailable for comment. ®

Reducing the cost and complexity of web vulnerability management

More from The Register

next story
PORTAL TO ELSEWHERE scried in small galaxy far, far away
Supermassive black hole dominates titchy star formation
Boffins say they've got Lithium batteries the wrong way around
Surprises at the nano-scale mean our ideas about how they charge could be all wrong
Edge Research Lab to tackle chilly LOHAN's final test flight
Our US allies to probe potential Vulture 2 servo freeze
Europe prepares to INVADE comet: Rosetta landing site chosen
No word yet on whether backup site is labelled 'K'
Cracked it - Vulture 2 power podule fires servos for 4 HOURS
Pixhawk avionics juice issue sorted, onwards to Spaceport America
Archaeologists and robots on hunt for more Antikythera pieces
How much of the world's oldest computer can they find?
Who wants to be there as history is made at the launch of our LOHAN space project?
Two places available in the chase plane above the desert
prev story

Whitepapers

Secure remote control for conventional and virtual desktops
Balancing user privacy and privileged access, in accordance with compliance frameworks and legislation. Evaluating any potential remote control choice.
WIN a very cool portable ZX Spectrum
Win a one-off portable Spectrum built by legendary hardware hacker Ben Heck
Storage capacity and performance optimization at Mizuno USA
Mizuno USA turn to Tegile storage technology to solve both their SAN and backup issues.
High Performance for All
While HPC is not new, it has traditionally been seen as a specialist area – is it now geared up to meet more mainstream requirements?
The next step in data security
With recent increased privacy concerns and computers becoming more powerful, the chance of hackers being able to crack smaller-sized RSA keys increases.